$21bn market targeted as TRX receives trial approval
York-based Tissue Regenix (TRX), the regenerative medical device company, has announced that approval has been given for a clinical research trial of its dCELL dermis matrix, which will examine its effectiveness in treating acute wounds, in addition to chronic wounds which was previously evaluated in a clinical study.
This trial marks an important milestone in Tissue Regenix’s plans to target the global market for chronic and acute wound care, which research firm Kalorama estimates could be worth around $21 billion by 2015.
Finding more effective ways to treat acute wounds, including surgical incisions and traumatic injuries such as lacerations, abrasions, avulsions, penetrations, bites or burn injuries, would save the NHS significant sums of money, improve patient recovery times and promote more successful healing.
The clinical study will be conducted by University Hospital of South Manchester NHS Foundation Trust and will involve a series of six-week trials on 50 healthy human patients, to investigate the responsiveness of acute wounds to Tissue Regenix’s dCELL dermis matrix and to clarify if dCELL dermis improves the closure of acute wounds compared to “normal” wound healing and other options.
Tissue Regenix’s dCELL dermis works by taking human donor skin and removing the DNA and cells, using the patented dCELL process to leave a dermis matrix that can be placed over the wound to aid natural healing by attracting the patient’s own cells to the wound area.
Antony Odell, managing director of Tissue Regenix Group plc, commented: “We are delighted that this clinical trial can now proceed.
“Finding more effective ways to treat acute wounds could significantly improve the efficacy and speed of patient recovery times and save the NHS and other healthcare providers’ significant sums of money.
“This builds on the work we have already been undertaking in collaboration with Dr Bayat and his team in Manchester on chronic wounds, with a clinical study which investigated successfully the efficacy of Tissue Regenix dCELL dermis matrix in healing chronic wounds such as venous ulcers.”
This was posted in Bdaily's Members' News section by Mark Lane .
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular Yorkshire & The Humber morning email for free.